PCSK9 inhibitors lower LDL cholesterol and cardiovascular event rates, reserved for high-risk patients with inadequate responses to statins and ezetimibe or those intolerant to statins due to high cost.

This paper reviews the evolution of LDL-C targets in lipid management, highlighting the efficacy of statins and newer therapies in reducing ASCVD risk and advocating for lower LDL-C goals.

Bempedoic acid effectively lowers LDL-C and reduces major cardiovascular events in high-risk patients with statin intolerance, showing significant benefits while having fewer myalgia and diabetes events compared to placebo.

Ficus religiosa, or sacred fig, is a medicinal tree with diverse bioactive compounds, traditionally used to treat various ailments. Future research should focus on its structure-function relationships and signaling pathways.

Lipid-lowering therapies reduce platelet reactivity and thrombus formation, improving clinical outcomes. This review highlights the mechanisms, effects of various therapies, and emphasizes future research needs in optimizing platelet function management.

Resistance exercise is essential for cardiovascular health, offering benefits in strength, body composition, and disease management. Incorporating it into clinical practice enhances preventive strategies for cardiovascular risk.

GLP-1 receptor agonists demonstrate promise in managing type 2 diabetes and reducing cardiovascular risk, but further research is needed to optimize treatment regimens and enhance long-term patient outcomes.

Recent data suggest that reducing salt, incorporating marine oils, and following specific dietary patterns (e.g., plant-based, dairy, fat-adjusted) may help lower blood pressure, especially with weight reduction.

Alzheimer's disease is linked to lipid metabolism dysregulation, with cholesterol, sphingolipids, and fatty acids influencing key pathologies. Targeting lipid metabolism offers potential therapeutic strategies, including diets, statins, and novel compounds.

Secondary dyslipidemia necessitates identifying and addressing underlying causes before initiating lipid-lowering therapy, focusing on dietary factors, metabolic diseases, and medication side effects.

Many patients with atherosclerotic cardiovascular disease (ASCVD) do not achieve recommended LDL-C levels due to underutilization of lipid-lowering therapy; multifaceted interventions are needed for optimal management.

The review explores lipid metabolism's role in obesity-related disorders in dogs and cats, emphasizing gut microbiota and management strategies including nutritional interventions for effective obesity treatment.

Statins are key for ASCVD prevention, with proven efficacy. Alternative therapies like ezetimibe and PCSK9 inhibitors, along with emerging treatments, enhance lipid management and cardiovascular outcomes.

PCSK9 inhibitors are effective in lowering LDL cholesterol and offer significant benefits for high-risk patients. Despite high costs and mixed cost-effectiveness results, they remain a valuable treatment option.

Higher triglycerides are a risk factor for acute pancreatitis, while lower HDL-C is both a risk factor and a consequence. HDL-C modulation may aid in prevention and treatment.

Familial hypobetalipoproteinemia 1 (FHBL1) is a rare genetic disorder impairing lipoprotein formation, causing hypolipidemia and fat malabsorption, leading to severe complications. Treatment is primarily palliative.

Acute pancreatitis (AP) management involves assessing severity, fluid resuscitation, pain control, and ERCP for gallstone cases. Hypertriglyceridemia management is crucial in AP treatment to prevent recurrence.

Elevated Lp(a) levels are crucial in atherosclerosis and aortic stenosis, contributing to cardiovascular risks. Emerging therapies targeting Lp(a) offer hope for improved management and risk reduction.

EPA-only formulations demonstrate superior efficacy in reducing cardiovascular events compared to mixed O3FA or DHA formulations, likely due to unique mechanisms beyond lipid reduction.